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Abstract
Cyclic AMP (cAMP) inhibits the proliferation of several tumor cells. We previously reported an antiproliferative effect of PKA
I-selective cAMP analogs (8-PIP-cAMP and 8-HA-cAMP) on two human cancer cell lines of different origin. 8-Cl-cAMP,
another cAMP analog with known antiproliferative properties, has been investigated as a potential anticancer drug. Here,
we compared the antiproliferative effect of 8-Cl-cAMP and the PKA I-selective cAMP analogs in three human cancer cell lines
(ARO, NPA and WRO). 8-Cl-cAMP and the PKA I-selective cAMP analogs had similarly potent antiproliferative effects on the
BRAF-positive ARO and NPA cells, but not on the BRAF-negative WRO cells, in which only 8-Cl-cAMP consistently inhibited
cell growth. While treatment with the PKA I-selective cAMP analogs was associated with growth arrest, 8-Cl-cAMP induced
apoptosis. To further investigate the actions of 8-Cl-cAMP and the PKA I-selective cAMP analogs, we analyzed their effects
on signaling pathways involved in cell proliferation and apoptosis. Interestingly, the PKA I-selective cAMP analogs, but not
8-Cl-cAMP, inhibited ERK phosphorylation, whereas 8-Cl-cAMP alone induced a progressive phosphorylation of the p38
mitogen-activated protein kinase (MAPK), via activation of AMPK by its metabolite 8-Cl-adenosine. Importantly, the pro-
apoptotic effect of 8-Cl-cAMP could be largely prevented by pharmacological inhibition of the p38 MAPK. Altogether, these
data suggest that 8-Cl-cAMP and the PKA I-selective cAMP analogs, though of comparable antiproliferative potency, act
through different mechanisms. PKA I-selective cAMP analogs induce growth arrest in cells carrying the BRAF oncogene,
whereas 8-Cl-cAMP induce apoptosis, apparently through activation of the p38 MAPK pathway.
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Introduction
Cyclic AMP (cAMP) is an ancient and ubiquitous chemical
messenger, being found both in prokaryotes and eukaryotes. In
vertebrates it is a major intracellular mediator of neurotransmitters
and hormones and regulates essential cell functions, such as
contraction, secretion and replication. While cAMP has an
antiproliferative effect on most cell types, it provides an opposite,
i.e. pro-mitotic, stimulus for neurons and several cells of endocrine
origin [1,2]. Not surprisingly then, genes encoding key elements of
the cAMP pathway act as oncogenes or oncosuppressors, most
exquisitely in endocrine cells [3,4,5,6,7,8,9,10]. Moreover, an
upregulation of type I isoforms of the cAMP-dependent protein
kinase A (PKA) has been documented in several malignancies [11].
Since cAMP has an antiproliferative effect on tumor cells, cell-
permeable cAMP analogs have been considered for the therapy of
human cancer [11]. 8-Cl-cAMP, the best studied of these
compounds, has antiproliferative properties both in vitro and in
vivo and has been evaluated in phase I/II clinical trials [11,12,13].
Yet, despite the well-documented effects of 8-Cl-cAMP, there is no
common agreement on its mechanism of action. In the pioneering
studies by the group of Yoon Cho-Chung it was in fact shown that
8-Cl-cAMP modifies the ratio of the PKA regulatory (R) subunits
(type I vs. type II) by decreasing the levels of type I R subunits
[11,14]. Though this phenomenon was deemed responsible for the
antiproliferative effect of 8-Cl-cAMP, the results of more recent
studies suggest that the effects of 8-Cl-cAMP are instead mediated
by its metabolite 8-Cl-adenosine and are independent of PKA
activation and/or alterations of the ratio between type I and type
II R subunits [15,16,17,18].
In a previous work we found that a pair of site-specific cAMP
analogs (8-PIP-cAMP and 8-HA-cAMP), which, when used in
combination, selectively activate PKA I, had a potent antiprolif-
erative effect on two BRAF-positive carcinoma cell lines (ARO
and NPA), but not on the BRAF-negative WRO cells [19]. In this
study we compared the effects of 8-Cl-cAMP and these PKA I-
selective cAMP analogs on the same carcinoma cell lines (ARO,
NPA and WRO), by looking at parameters such as cell growth,
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apoptosis and modifications of key signaling cascades that might
be implicated in their antiproliferative effects.
Results
Effect of 8-Cl-cAMP or the PKA I-selective cAMP analogs
on cell proliferation
First, we compared the antiproliferative effect of 8-Cl-cAMP and
the PKA I-selective cAMP analogs. For this purpose, we treated
ARO (colon cancer), NPA (melanoma) andWRO (follicular thyroid
carcinoma) cells with different concentrations of 8-Cl-cAMP or the
PKA I-selective cAMP analogs for various periods of time (24–96 h)
and evaluated cell viability utilizing the MTT assay. The results
indicated that both treatments were similarly potent in inhibiting
the growth of ARO and NPA cells, whereas only 8-Cl-cAMP had a
consistent antiproliferative effect on WRO cells (Figure 1). The
effect of both treatments reached a maximum after 72–96 h of
incubation (data not shown) and was dose-dependent, with IC50
values of 55.3 mM in ARO and 84.8 mM in NPA cells for the PKA
I-selective cAMP analogs and between 2.3 and 13.6 mM for 8-Cl-
cAMP in all three cell lines. Consistent with the previous finding
that the antiproliferative effect of 8-Cl-cAMP is PKA-independent
and at least partially mediated by its metabolite 8-Cl-adenosine
[15,16,17,18], the effect of 8-Cl-cAMPwas significantly inhibited by
treatment with the phosphodiesterase inhibitor IBMX, which blocks
the conversion of 8-Cl-cAMP to 8-Cl-adenosine. On the contrary,
IBMX did not modify the antiproliferative effect of the PKA I-
selective cAMP analogs (Figure S1). Furthermore, the antiprolifer-
ative effect of 8-Cl-cAMP did not appear to be mediated by PKC, as
treatment with a PKC inhibitor did not modify the response to 8-Cl-
cAMP (Figure S2).
Effect of 8-Cl-cAMP or the PKA I-selective cAMP analogs
on cell cycle progression and apoptosis
Subsequently, we evaluated whether the antiproliferative effect
of 8-Cl-cAMP and the PKA I-selective cAMP analogs was
associated with growth arrest and/or apoptosis. This issue was
addressed by a combination of approaches.
First, we analyzed the effects of 8-Cl-cAMP and the PKA I-
selective cAMP analogs on cell cycle and apoptosis by flow
cytometry analysis of the nuclear DNA content. For this purpose,
ARO, NPA and WRO cells were treated with either type of cAMP
analog(s) for different periods of time and analyzed after DNA
staining with propidium iodide. 8-Cl-cAMP treatment was
associated with a reduction of cells in G0/G1 and an
accumulation of cells in S phase. In addition, it was accompanied
by a significant increase in the fraction of apoptotic cells, i.e. those
with a sub-G0/G1 DNA content. By contrast, exposure to the
PKA I-selective cAMP analogs did not cause a significant increase
in apoptosis. The only appreciable effect of the PKA I-selective
cAMP analogs was a slight increase in the number of cells in G0/
G1 (statistically significant in ARO cells) and a tendency towards a
reduction of the cells in S and G2/M phases, both compatible with
accumulation in G0/G1 (Table 1).
Next, we analyzed the release of histone-bound DNA fragments
into the cytosol, as a marker of apoptotic DNA fragmentation. ARO,
NPA andWRO cells were exposed to sub-maximal concentrations of
the PKA I-selective cAMP analogs or 8-Cl-cAMP, and the amount of
nucleosomes in the cytoplasm was evaluated by a specific ELISA. 8-
Cl-cAMP treatment caused a significant increase in DNA fragmen-
tation in all three cell lines that was detectable starting from 48 h of
incubation. On the contrary, no induction of DNA fragmentation
was observed in cells treated with the PKA I-selective cAMP analogs
(Fig 2A and data not shown).
Finally, as apoptosis is associated with caspase activation [20],
we examined the effect of both treatments on the activity of
caspase 3/7, which was measured utilizing a luminescent assay. A
significant increase in caspase 3/7 activity was detected in ARO,
NPA and WRO cells exposed to 8-Cl-cAMP starting from 24 h of
Figure 1. Antiproliferative effect of 8-Cl-cAMP (A) or the PKA I-
selective cAMP analogs (B). ARO, NPA and WRO cells were cultured
for 72 h in the presence of the indicated concentrations of either type
of cAMP analog(s) and cell viability was determined utilizing the MTT
assay. PKA I, PKA I-selective analogs used at equimolar concentrations.
doi:10.1371/journal.pone.0020785.g001
Table 1. Effects of 8-Cl-cAMP and the PKA I-selective analogs
on cell cycle.
Cell cycle phase (% of cells)
Cell line Treatment Sub-G0/G1 G0/G1 S G2/M
ARO control 1.0460.19 49.3765.56 16.2563.4 32.6266.99
8-Cl-cAMP 5.1660.24{ 38.8862.69* 22.1062.79* 26.8864.21
PKA I 1.1160.20 59.0364.59* 12.5261.10 24.2964.26
NPA control 1.8160.15 57.2162.06 20.5661.44 19.661.17
8-Cl-cAMP 9.2562.08{ 40.8161.38{ 27.3761.52{ 21.5961.86
PKA I 2.8860.69 61.3461.73 17.8161.24 17.1961.26
WRO control 3.3060.25 50.1160.69 16.0661.79 30.9461.77
8-Cl-cAMP 17.6361.35{ 27.3462.36{ 23.6061.75{ 31.8162.21
PKA I 6.16560.50 54.8063.35 15.2861.71 23.9964.90
Cells were treated with 8-Cl-cAMP (100 mM) or the PKA I-selective cAMP analogs
(100 mM each) for 72 h. PKA I, PKA I-selective cAMP analogs. *, P,0.05 vs.
control. {, P,0.01 vs. control. {, P,0.001 vs. control.
doi:10.1371/journal.pone.0020785.t001
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treatment, but not in the same cells treated with the PKA I-
selective cAMP analogs (Figure 2B).
Taken together these data suggested that 8-Cl-cAMP but not
the PKA I-selective cAMP analogs induced apoptosis in ARO,
NPA and WRO cells.
Apoptotic pathways activated by 8-Cl-cAMP
To investigate the pathway involved in the apoptosis induced by
8-Cl-cAMP, we evaluated the activity of caspase 8 (extrinsic
pathway) and caspase 9 (intrinsic pathway) utilizing specific
luminescent assays. An early and transient (10 min–1 h) activation
of caspase 8, but not of caspase 9, was observed (Figure 3),
suggesting that 8-Cl-cAMP may induce the extrinsic pathway.
However, these two caspases did not show any activation at later
time points (24–48 h) (data not shown).
Effect of 8-Cl-cAMP or the PKA I-selective cAMP analogs
on the levels of PKA subunits
Since it has been reported that 8-Cl-cAMP causes a down-
regulation of RIa and an up-regulation of RIIb subunits [14,21],
we compared the effects of 8-Cl-cAMP and the PKA I-selective
cAMP analogs on the expression of the PKA R subunits. For this
purpose, ARO, NPA and WRO cells were stimulated with 8-Cl-
cAMP or the PKA I-selective cAMP analogs for different periods
of time and the levels of RIa, RIIa and RIIb were evaluated by
Western blot analysis utilizing isoform-specific antibodies. Treat-
ment of ARO, NPA and WRO cells with either 8-Cl-cAMP or the
PKA I-selective cAMP analogs was associated with a reduction of
the expression levels of the RIa subunit, whereas the levels of the
remaining subunits were not affected (Figure 4).
Effect of 8-Cl-cAMP or the PKA I-selective cAMP analogs
on ERK 1/2 and Akt
In an effort to better understand the mechanism of action of 8-
Cl-cAMP and the PKA I-selective cAMP analogs, we then
examined the effect of both types of treatment on two key signaling
cascades that are involved in cell growth, i.e. the extracellular
signal-regulated kinase 1/2 (ERK) mitogen activated protein
kinase (MAPK) pathway and the phosphatidylinositol 3-kinase
(PI3K)/Akt pathway.
ERK1/2 are well-characterized MAPKs that are activated in
response to growth stimuli and play important roles in neoplastic
transformation [22]. In addition, cAMP has been found to inhibit
ERK 1/2 activation in several of the cell types where it has an
antiproliferative effect [1,2]. This seems to be the case also in ARO
and NPA cells, where, as we have previously shown, the
antiproliferative effect of the PKA I-selective cAMP analogs is
associated with an inhibition of ERK 1/2 phosphorylation at
Thr202/Tyr204 [19]. On this basis, we evaluated the effect of 8-
Cl-cAMP treatment on ERK phosphorylation at Thr202/Tyr204
by Western blot analysis with a phospho-specific antibody.
Analysis of ERK activation at early time points revealed transient
increases for both treatments (Figure S3). At variance with what
we previously observed in response to the PKA I-selective cAMP
analogs, chronic exposure to 8-Cl-cAMP was not associated with a
late and persistent inhibition of ERK phosphorylation (Figure 5).
Figure 2. Effect of 8-Cl-cAMP or PKA I-selective cAMP analogs on DNA fragmentation and caspase 3/7 activation. A: effect on DNA
fragmentation. Cells were exposed to 8-Cl-cAMP (100 mM) or the PKA I-selective cAMP analogs (100 mM each) for 48 h and the release of histone-
bound DNA fragments into the cytosol was evaluated by a specific ELISA. Data are from three independent experiments. B: effect on caspase 3/7.
Cells were exposed to 8-Cl-cAMP (100 mM) or the PKA I-selective cAMP analogs (100 mM each) for 72 h and caspase 3/7 activity was determined with
a luminescent assay. Data are from three independent experiments. * P,0.001 vs. control cells. All data are expressed as the variation versus control
cell culture without drugs.
doi:10.1371/journal.pone.0020785.g002
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Another protein that has been implicated in cell proliferation is
the serine/threonine kinase Akt, which is activated by PI3K
products and phosphorylation at Ser473 and Thr308 [23]. We
therefore evaluated the effect of 8-Cl-cAMP and the PKA I-
selective cAMP analogs on Akt phosphorylation at Ser473 and
Thr308, indicative of its activation. Consistent with what we
previously reported [19], treatment with 8-Cl-cAMP or the PKA
I-selective analogs did not cause relevant modifications of Akt
phosphorylation at early time-points (Figure S3) and for up to 72 h
(data not shown).
Effect of 8-Cl-cAMP or the PKA I-selective cAMP analogs
on the p38 MAPK
8-Cl-cAMP has been shown to induce p38 MAPK phosphor-
ylation in HL60 and HeLa cells [24,25]. Therefore, we evaluated
the effect of 8-Cl-cAMP and the PKA I-selective cAMP analogs on
p38 MAPK phosphorylation. We found that treatment of ARO,
NPA and WRO cells with 8-Cl-cAMP was associated with a
progressive increase in p38 MAPK phosphorylation, beginning at
24 h of incubation (Figure 6). On the contrary, treatment with the
PKA I-selective cAMP analogs did not modify the phosphoryla-
tion state of the p38 MAPK (Fig 6), except for minor and transient
increases that did not reach statistical significance. Moreover,
treatment with 8-Cl-cAMP or the PKA I-selective analogs did not
cause modifications of p38 MAPK phosphorylation at early time
points (Figure S3).
Finally, we evaluated whether the pro-apoptotic effect of 8-Cl-
cAMP was dependent on p38 MAPK activation. To this aim, we
treated for 48–72 h all three cell lines with 8-Cl-cAMP in the
presence or absence of selective p38 MAPK inhibitors (SB 202190
or SB203580) and analyzed the cell cycle distribution by flow
cytometry as described above. Interestingly, inhibition of the p38
MAPK largely prevented the pro-apoptotic effect 8-Cl-cAMP
(Figure 7).
Taken together, these data strongly suggest that the pro-
apoptotic effect of 8-Cl-cAMP on ARO, NPA and WRO cells is
mediated by the p38 MAPK.
Involvement of AMPK in the activation of p38 MAPK by
8-Cl-cAMP
A recent study [25] has reported that the antiproliferative effects
of 8-Cl-cAMP could be mediated by an activation of the AMP-
activated protein kinase (AMPK) after its metabolization to 8-Cl-
adenosine. To verify this hypothesis we evaluated the effects of
both an activator, AICAR, and an inhibitor, Compound C, of
AMPK. Treatment with AICAR mimicked the effects of 8-Cl-
Figure 3. Effect of 8-Cl-cAMP on caspase 8 and 9. ARO, NPA and WRO cells were exposed to 8-Cl-cAMP (200 mM) for different periods of time
and the activities of caspase 8 and 9 were measured utilizing specific luminescent assays. Data are from three to six independent experiments.
* P,0.05 vs. basal. ** P,0.01 vs. basal. *** P,0.001 vs. basal. All data are expressed as the variation versus baseline.
doi:10.1371/journal.pone.0020785.g003
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Figure 4. Effect of 8-Cl-cAMP or PKA I-selective cAMP analogs on the levels of PKA regulatory subunits. ARO, NPA and WRO cells were
treated with 8-Cl-cAMP (100 mM) or the PKA I-selective cAMP analogs (100 mM each) for the indicated periods of time. The levels of RIa, RIIa and RIIb
were measured by Western blot analysis. Shown are representative Western blots (A) as well as the results of the densitometric analysis of four
independent experiments (B). * P,0.01 vs. basal. ** P,0.001 vs. basal. These data are expressed as variation versus baseline.
doi:10.1371/journal.pone.0020785.g004
Figure 5. Effect of 8-Cl-cAMP or the PKA I-selective cAMP analogs on ERK phosphorylation. ARO, NPA and WRO cells were treated with 8-
Cl-cAMP (100 mM) or the PKA I-selective cAMP analogs (100 mM each) for the indicated periods of time. The levels ERK 1/2 phosphorylated at Thr202/
Tyr204 and total ERK were measured by Western blot analysis. Shown are representative Western blots as well as the densitometric analysis of three
to four independent experiments. The P-ERK/total-ERK ratios are expressed as the relative variation versus the basal levels of each single experiment.
* P,0.05 vs. basal. ** P,0.01 vs. basal.
doi:10.1371/journal.pone.0020785.g005
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cAMP on p38 MAPK phosphorylation and on caspase 3/7
activity. In addition, Compound C was able to largely prevent
both the phosphorylation of p38 MAPK and the activation of
apoptosis induced by 8-Cl-cAMP (Figure 8).
Discussion
cAMP analogs inhibit the proliferation of several tumor cells. The
best studied of these compound is 8-Cl-cAMP, which has a
demonstrated antiproliferative effect both in vitro and in vivo and has
been evaluated in phase I/II clinical trials [11,12,13]. In a recent
study, we have described the antiproliferative effect of a pair of
cAMP analogs selective for PKA I on human carcinoma cell lines
[19]. The goal of this work was to compare the effect of these cAMP
analogs to that of the well studied 8-Cl-cAMP and further
investigate their mechanism(s) of action. The results suggest that
8-Cl-cAMP and the PKA I-selective cAMP analogs, though of
similar potency, differ in cell-type selectivity and mechanism(s) of
Figure 6. Effect of 8-Cl-cAMP on p38 MAPK phosphorylation. ARO, NPA and WRO cells were treated with 8-Cl-cAMP (100 mM) or the PKA I-
selective cAMP analogs (100 mM each) for the indicated periods of time. The levels of phosphorylated and total p38 MAPK were measured by Western
blot analysis. Shown are representative Western blots as well as the densitometric analysis of three independent experiments. P-p38/total-p38 ratio is
normalized to basal levels. * P,0.05 vs. basal. ** P,0.01 vs. basal. *** P,0.001 vs. basal.
doi:10.1371/journal.pone.0020785.g006
Figure 7. Effect of p38 MAPK inhibitors on the apoptosis induced by 8-Cl-cAMP. Cells were stimulated with 8-Cl-cAMP (100 mM) either in
the presence or in the absence of p38 MAPK inhibitors (10 mM SB203580 or SB202190) for 72 h and apoptosis was evaluated by flow cytometry
analysis after propidium iodide staining. Data are from at least three independent experiments. Data are expressed as the variation versus control cell
culture. * P,0.05 and ** P,0.001 vs. cells treated with 8-Cl-cAMP alone.
doi:10.1371/journal.pone.0020785.g007
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action. The PKA I-selective cAMP analogs induce growth arrest,
but not apoptosis, and, as we have previously shown, their effects
appear to be mediated by a PKA-dependent inhibition of ERK
activation. By contrast, 8-Cl-cAMP effects are most likely exerted by
its metabolite 8-Cl-adenosine, are independent of PKA activation,
and are apparently mediated by AMPK activation and subsequent
p38 MAPK-dependent induction of apoptosis.
Our data indicate that 8-Cl-cAMP and the PKA I-selective
cAMP analogs have a similarly potent antiproliferative effect,
suggesting that both of them may retain a potential for cancer
therapy. The PKA I-selective cAMP analogs seem to require the
presence of constitutive ERK activation, as suggested by their being
highly active only in the BRAFV600E-mutated ARO and NPA cells,
where they inhibit ERK phosphorylation. By contrast, 8-Cl-cAMP
strongly inhibits cell growth also in the BRAF-negative WRO cells,
suggesting that it may be effective in a broader range of cancer cells.
Several findings indicate that 8-Cl-cAMP and the PKA I-
selective cAMP analogs act via different mechanisms. First, the
effect of 8-Cl-cAMP appears to be principally mediated, in
agreement with previous observations [15,16,17,18], by its
metabolite 8-Cl-adenosine, acting via AMPK, and not by
stimulation of PKA, as suggested by the effect of IBMX and of
selective AMPK activation/inhibition; on the contrary, IBMX
does not modify the antiproliferative response to the PKA I-
selective cAMP analogs. Second, 8-Cl-cAMP and the PKA I-
selective cAMP analogs produce dissimilar modifications of cell
cycle. In particular, 8-Cl-cAMP, but not the PKA I-selective
cAMP analogs, induce apoptosis. Third, the PKA I-selective
cAMP analogs, but not 8-Cl-cAMP, reduce ERK phosphorylation
in ARO and NPA cells. Fourth, 8Cl-cAMP, but not the PKA I-
selective cAMP analogs, increase p38 MAPK phosphorylation.
The mechanism of action of 8-Cl-cAMP is highly debated. Cho-
Chung and colleagues have done a considerable amount of work
on this topic, the results of which indicate that 8-Cl-cAMP induces
growth inhibition by increasing the RI to RII ratio [14,21]. On the
other hand, more recent studies suggest that this regulation is not
the major cause of the observed growth inhibition [17]. In this
report we find that 8-Cl-cAMP reduces the expression of RIa in
ARO, NPA and WRO cells. However, we find that IBMX, which
blocks the conversion of 8-Cl-cAMP to 8-Cl-adenosine, a
metabolite unable to activate PKA, significantly reduces the
antiproliferative effect of 8-Cl-cAMP.
A recent study [25] has demonstrated that 8-Cl-adenosine is
able to stimulate AMPK, so we investigated the involvement of
this pathway in 8-Cl-cAMP-induced apoptosis. Our data show
that the induction of apoptosis by 8-Cl-cAMP is accompanied by
the activation of caspase 3/7, and similar results were obtained by
AICAR, an activator of AMPK. Furthermore, Compound C, an
AMPK inhibitor, prevents the caspase 3/7 induction of both
AICAR and 8-Cl-cAMP respectively. In the end, we propose that
the pro-apoptotic effect of 8-Cl-cAMP is mediated by AMPK.
In addition, we show that the pro-apoptotic effect of 8-Cl-cAMP is
accompanied by a progressive increase of p38 MAPK phosphory-
lation. The p38 MAPK is a key regulator of cell survival [26,27], and
has been implicated in the pro-apoptotic effect of 8-Cl-cAMP in
HL60 andHeLa cells [24,25]. To investigate if p38MAPKactivation
is dependent by AMPK we employed an activation/inhibition
strategy similar to that one adopted for caspase 3/7. Since AMPK
Figure 8. Involvement of AMPK in the activation of p38 MAPK and caspase 3/7 by 8-Cl-cAMP. ARO, NPA and WRO cells were stimulated
with 8-Cl-cAMP (100 mM) or an AMPK activator (AICAR, 1 mM) for 72 h either in the presence or absence of pretreatment with an AMPK inhibitor
(Compound C, 2.5 mM). A: the levels of phosphorylated and total p38 MAPK were measured by Western blot analysis. Shown are the results of
representative Western blot experiments as well as the densitometric analysis of three independent experiments. Data are normalized to control
levels. B: caspase 3/7 activity was determined with a luminescent assay. Shown are results from at least three independent experiments. Data are
normalized to control cell culture. Legend: A: control, B: 8-Cl-cAMP, C: AICAR, D: Compound C, E: 8-Cl-cAMP + Compound C, F: AICAR + Compound C.
* P,0.05, ** P,0.01, *** P,0.001 vs. control. # P,0.05, ## P,0.01, ### P,0.001 vs. 8-Cl-cAMP. 1 P,0.05, 11 P,0.01, 111 P,0.001 vs. AICAR.
doi:10.1371/journal.pone.0020785.g008
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blockade largely prevented and AMPK activation mimicked the
effects of 8-Cl-cAMP on the p38 MAPK, our data strongly suggest
that 8-Cl-cAMP after the conversion in its metabolite 8-Cl-adenosine
activates the p38 MAPK through the stimulation of AMPK.
In an attempt to clarify the pathway leading to caspase 3/7
activation, we measured the activity of the upstream caspases 8 and 9,
which are involved in the extrinsic and intrinsic apoptotic pathways,
respectively. Whereas no activation of caspase 9 was observed, an
early and only transient (5 min–1 h) activation of caspase 8 was
detected. These data might indicate an involvement of the extrinsic
pathway in the pro-apoptotic effects of 8-Cl-cAMP. However, given
the observed long delay between the activation of caspase 8 and 3/7,
and the transient nature of caspase 8 activation, it is possible that
other mechanisms, likely independent of upstream caspases, might be
involved in the activation of caspase 3/7. Interestingly, although the
mechanisms by which the p38 MAPK can activate caspases are not
fully elucidated, a possible direct activation of caspase 3 by the p38
MAPK has also been reported [28].
In conclusion, our data indicate that both 8-Cl-cAMP and the
PKA I-selective cAMP analogs have a similarly potent antiprolif-
erative effect on cancer cell lines of different origin. Thus, they
both retain a potential as anticancer drugs. 8-Cl-cAMP appears to
be effective in a broader range of cell types and induces apoptosis.
On the other hand, the mechanism(s) of action of 8-Cl-cAMP and
the PKA I-selective cAMP analogs are different, suggesting that
they may have dissimilar pharmacological and toxicological
profiles, as well as unique antitumoral properties. Future in vivo
experiments will be required to compare their efficacy and
tolerability in preclinical cancer models.
Materials And Methods
Chemicals
Cell culture reagents were purchased from Invitrogen (San
GiulianoMilanese, Italy). 8-chloroadenosine-39,59-cyclic monophos-
phate (8-Cl-cAMP), 8-piperidinoadenosine-39,59-cyclic monophos-
phate (8-PIP-cAMP) and 8-hexylaminoadenosine-39,59cyclic mono-
phosphate (8-HA-cAMP) were purchased from BIOLOG Life
Science Institute (Bremen, Germany). The BCA kit and nitrocellu-
lose membranes were purchased from Pierce Biotechnology (Rock-
ford, IL). PKARIa, PKARIIa, PKARIIb and b-actin antibodies
were purchased from BD Biosciences Pharmingen (Milan, Italy).
Phospho-ERK, phospho-Akt, phospho-p38 MAPK, ERK, Akt and
p38 MAPK antibodies were purchased from Cell Signaling
Technology (Beverly, MA). HRP conjugated mouse and rabbit
secondary antibodies were purchased from Chemicon International
(Temecula, CA). The ECL-plus kit was purchased from Amersham
Biosciences Europe (Freiburg, Germany). The Cell Death
Detection ELISA Plus kit was purchased from Roche Applied
Science (Mannheim, Germany). The CellTiter-Blue cell viability
and the Caspase-Glo 3/7, 8 or 9 assays were purchased from
Promega Corporation (Madison, WI, USA). 4-(4-fluorophenyl)-2-
(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580)
was purchased from Biosource (Nivelles, Belgium). 3-isobutyl-1-
methylxanthine (IBMX), 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-
5-(4-pyridyl)-1H-imidazole (SB202190), bisindolyl-maleimide I
(GF109203X), AICAR, 6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-
pyridin-4-ylpyrazolo[1,5-a]pyriimdine (Compound C) and all
other reagents were purchased from Sigma-Aldrich (Milan, Italy).
Cell culture
ARO, NPA and WRO cells were kindly provided by I.
Bongarzone (Milan, Italy). A recent DNA profiling analysis has
revealed that ARO cells match the HT-29 colon cancer cell line
and NPA cells match the M14/MDA-MB-435S melanoma cell
line [29]. WRO cells derive from a follicular thyroid carcinoma
[30]. All cells were maintained in DMEM medium supplemented
with 10% FCS, 1% penicillin and 1% streptomycin at 37uC in a
humidified atmosphere with 5% CO2.
Selective activation of PKA I
To selectively activate PKA I, we utilized the commonly used
strategy of simultaneously utilizing two distinct cAMP analogs, i.e.
8-piperidinoadenosine-39,59-cyclic monophosphate (8-PIP-cAMP)
and 8-hexylaminoadenosine-39,59cyclic monophosphate (8-HA-
cAMP), each with high selectivity for binding to either site A (8-
PIP-cAMP) or B (8-HA-cAMP) of type I PKA R subunits [19].
Proliferation assay
Cell proliferation was evaluated utilizing the 3-(4,5-dimetylthia-
zole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as previ-
ously described [19]. Briefly, cells were seeded in 96-well plates, and
24 h after plating were treated with the indicated concentrations of
8-Cl-cAMP or the PKA I-selective cAMP analogs (8-PIP-cAMP + 8-
HA-cAMP). For inhibition of PKC, cells were incubated for 30 min
with GF109203x prior to addition of 8-Cl-cAMP or the PKA I-
selective cAMP analogs. MTT (0.5 mg/mL) was added to cells three
hours before measurement, and formazan crystals, formed by
mitochondrial reduction of MTT, were solubilized in DMSO/
ethanol 1:1. Relative growth was calculated from the absorbance
at 550 nm utilizing the following equation: Relative growth
(%)= (OD550nm of treated wells/OD550nm of control wells)6100.
Detection of apoptotic DNA fragmentation
DNA fragmentation was evaluated utilizing the Cell Death
Detection ELISA Plus kit. This assay provides a quantitative
determination of histone-associated DNA fragments (mono- and
oligo-nucleosomes) in the cytoplasmatic fraction of cell lysates.
Briefly, cells were seeded in 96-well plates and 24 h later treated
with 8-Cl-cAMP or the PKA I-selective cAMP analogs for 48 h.
The samples were then processed and analyzed in triplicate,
according to the manufacturer’s instructions.
Determination of caspase activities
Caspase activity was measured utilizing the luminescent Caspase-
Glo 3/7, 8 or 9 assays, following the manufacturer’s instructions.
Caspase 3/7 activity was normalized for the number of cells
contained in each well, determined utilizing the fluorometric
CellTiter-Blue cell viability assay. Activation levels of caspases 8
and 9 are expressed relative to non-treated samples. Luminescent and
fluorescent measurements were performed utilizing the Fluoroskan
Ascent FL multiplate reader (Thermo Labsystems, Helsinki, Finland).
Analysis of cell cycle by flow cytometry
The cells were harvested by trypsinization, washed in PBS and then
fixed with ice-cold 70% ethanol. Fixed cells were washed with PBS and
stained with PBS containing 40 mg/ml propidium iodide and 100 mg/
ml RNAse A at 37uC for 30 min. Samples were analyzed with the
FACSCalibur flow cytometer (Becton Dickinson, Buccinasco, Italy).
Western blot analysis
For detection of PKA regulatory subunits, cells were lysed in
modified RIPA buffer containing protease inhibitors (10 mM Tris-
HCl pH 7.5, 500 mM NaCl, 0.1% SDS, 1% NP40, 1% Na
deoxycholate, 2 mM EDTA, 2 mM Na2VO4, 2 mM Na4P2O7,
2 mM NaF). For detection of ERK, Akt, and p38 MAPK
phosphorylation, cells were lysed with SDS sample buffer
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(62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% Glycerol, 50 mM
DTT, 0.01% Bromophenol Blue), immediately heated for 5 min
at 95uC and sonicated. Protein concentration was determined
utilizing the BCA assay. Ten micrograms of protein extracts were
separated on 10% SDS polyacrylamide gels and electrotransfered
to nitrocellulose membranes. Membranes were blocked with TBS-
T +5% milk, probed with the indicated primary antibody
overnight at 4uC and incubated with an appropriate HRP-
conjugated secondary antibody for 1 h at room temperature. The
detection was performed utilizing the ECL-plus kit.
Statistical analysis
Values are expressed as mean 6 standard error. One-way or
two-way ANOVA followed by Bonferroni’s post-hoc test were
used, as appropriate, to evaluate differences between means. A P
value ,0.05 was considered statistically significant.
Supporting Information
Figure S1 Effect of phosphodiesterase inhibition. Cells
were preincubated with IBMX (50 mM) for 1 h before addition of
8-Cl-cAMP (100 mM) or the PKA I-selective cAMP analogs
(100 mM each) for 72 h. Cell viability was determined utilizing the
MTT assay. * P,0.001 vs. control. ** P,0.05 vs. control.
1 P,0.001 vs. cells treated with 8-Cl-cAMP alone.
(TIF)
Figure S2 Effect of PKC inhibition. Cells were preincubated
with a PKC inhibitor (GF109203x, 1 mM) for 1 h before addition
of 8-Cl-cAMP (100 mM) for 72 h. Cell viability was determined
utilizing the MTT assay.
(TIF)
Figure S3 Early effects of 8-Cl-cAMP and PKA I-
selective cAMP analogs on ERK, p38 MAPK and Akt
phosphorylation. Shown are the results of the densitometric
analysis of three independent Western blot experiments per
condition. Data are normalized to basal levels. Differences
between peak and basal values of ERK phosphorylation are
statistically significant in ARO, WRO and NPA cells after
stimulation with both 8-Cl-cAMP (P,0.05, P,0.01 and
P,0.05, respectively) and PKA I-selective analogs (P,0.001,
P,0.05 and P,0.05, respectively). Differences of Akt and p38
MAPK phosphorylation are not statistically significant.
(TIF)
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